Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Semaglutide in HFpEF: CAMEO-SEMA MRI

A 49-person CAMEO-SEMA substudy found improved cardiac filling measures with semaglutide, without testing hospitalization or survival.

Why we wrote this. Cardiac imaging can be mistaken for clinical-outcome proof, so we mapped what CAMEO-SEMA measured and what its 49-person substudy cannot answer.

In this article (6 sections)
  1. The substudy paired MRI with exercise measurements
  2. Both prespecified filling measures favored semaglutide
  3. Imaging changes are not clinical-outcome proof
  4. Weight loss may be part of the pathway
  5. What we don't yet know
  6. What this means for patients

In a 49-person cardiac MRI substudy, semaglutide improved two prespecified measures of heart filling and left-atrial function after 52 weeks compared with placebo. Participants had obesity-related heart failure with preserved ejection fraction (HFpEF). The study does not show whether those MRI changes reduce hospital admission or extend life[1].

The analysis came from the randomized CAMEO-SEMA trial. Left-atrial reservoir strain improved by 5.7 percentage points versus placebo, while an indexed measure of early left-ventricular filling improved by 0.64 per second. Both changes were associated with lower exercise pulmonary artery wedge pressure, a measure of filling pressure taken during invasive exercise testing[2].

The substudy paired MRI with exercise measurements

CAMEO-SEMA randomized people with obesity-related HFpEF to semaglutide or placebo. This cardiovascular magnetic resonance substudy included 49 participants, 28 of them women. Thirty-three received semaglutide and 16 received placebo. Each underwent cardiac MRI at baseline and 52 weeks, within one day of invasive exercise hemodynamic testing[1]. ClinicalTrials.gov lists the parent trial as NCT05371496.

HFpEF means heart-failure symptoms occur even though the percentage of blood ejected by the left ventricle remains in a conventionally preserved range. The ventricle can still be stiff, and pressure can rise sharply during activity. MRI can describe chamber shape, mass and movement without turning any one measure into a direct patient outcome.

The prespecified primary MRI endpoint was change in left-atrial reservoir strain. This describes how the atrium stretches while it receives blood. Another prespecified measure was early filling rate divided by left-ventricular end-diastolic volume, written as eFR/EDV. It describes early diastolic filling after accounting for chamber volume[2].

Both prespecified filling measures favored semaglutide

Compared with placebo, semaglutide improved left-atrial reservoir strain by 5.7 percentage points (95% confidence interval 0.3 to 9.7; p = 0.037). The indexed early-filling measure improved by 0.64 per second (95% CI 0.42 to 1.00; p below 0.0001)[1]. The first interval sits close to zero, which makes the modest sample and uneven group sizes relevant when judging precision.

Improvement in left-atrial reservoir strain correlated with reduced exercise filling pressure at r = -0.46. The correlation for improved left-ventricular filling dynamics was stronger at r = -0.65[2]. A negative value here means better imaging measures tended to accompany lower pressure. Correlation within a randomized trial still does not establish that one change caused the other.

Other prespecified MRI endpoints also favored semaglutide. The abstract reports reduced left-ventricular mass, geometry closer to the usual pattern, improved right-ventricular function and better movement measures across both ventricles[1]. The indexed abstract does not supply effect sizes for those endpoints, so their magnitude cannot be assessed from this record.

Imaging changes are not clinical-outcome proof

No clinical events were tested. The substudy measured cardiac structure, mechanics and filling pressure, so its better MRI findings may help explain earlier symptom and hemodynamic results without proving fewer hospital admissions, cardiovascular deaths or other major events.

This was a prespecified substudy, which is stronger than an analysis invented after results were seen. The sample remained small, however, and only 16 people were in the placebo group. A few unusual measurements can have more influence in groups of that size. The abstract does not report missing scans, adherence, adverse events or whether image readers were masked to treatment assignment.

Weight loss may be part of the pathway

Semaglutide can reduce body weight in people with obesity, and weight change can alter blood volume, cardiac workload and filling pressure. The abstract says myocardial changes may contribute to better hemodynamics, but it does not quantify how much of each MRI effect was independent of weight loss[2]. The study therefore cannot isolate a direct heart-muscle action from the wider consequences of metabolic and weight change.

Randomization supports the measured comparison. It does not identify every step between treatment, weight change, cardiac remodeling and how a patient feels during activity, which limits mechanistic interpretation without invalidating the observed endpoint differences.

What we don't yet know

We do not know whether the MRI differences persist after treatment stops or grow with longer follow-up. The abstract does not show whether the findings apply to HFpEF without obesity, to people excluded from invasive exercise testing or to more diverse clinical populations. It also does not provide funding and conflict disclosures in the indexed record available for this readout. Larger outcome trials would be needed to connect these imaging findings with hospitalization and survival.

What this means for patients

The findings give researchers a plausible cardiac explanation for some benefits seen in obesity-related HFpEF. They do not make cardiac MRI a treatment target for patients, and they do not support changing a prescription based on one strain or filling-rate number. HFpEF care depends on symptoms, congestion, kidney function, blood pressure and other conditions that require clinical assessment.

Our semaglutide evidence overview and semaglutide regulation summary cover the medicine more broadly. A cardiologist or prescribing clinician can explain whether the evidence is relevant to an individual diagnosis and current treatment plan.

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

What did semaglutide change in the CAMEO-SEMA substudy?

After 52 weeks, semaglutide improved left-atrial reservoir strain and an indexed measure of early left-ventricular filling compared with placebo. Other prespecified MRI measures also favored semaglutide, but the abstract does not provide effect sizes for all of them.

Did semaglutide reduce heart-failure hospitalization?

This 49-person MRI substudy did not report hospitalization, cardiovascular death or survival differences. It examined cardiac structure, movement and filling dynamics, so it cannot establish a benefit on major clinical outcomes.

What is left-atrial reservoir strain?

It is an imaging measure of how the left atrium stretches while receiving blood. The measure improved by 5.7 percentage points versus placebo, but it is not itself a symptom or a direct measure of how long someone lives.

Do these findings apply to everyone with HFpEF?

No. Participants had obesity-related HFpEF and underwent invasive exercise testing. The small substudy does not establish that the same MRI effects occur in HFpEF without obesity or in people who differ from the trial population.

Sources

  1. [1]CAMEO-SEMA cardiac MRI substudy, PubMed PMID 43000112Tier 1 · primary↩
  2. [2]CAMEO-SEMA cardiac MRI substudy, NCBI structured abstract recordTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars